Endocan Levels at Polycystic Ovary Syndrome and Periodontal Inflammation

Study Overview
=================
Brief Summary
-----------------
Periodontal diseases are chronic inflammatory disease occurred by the interaction between pathogenic microorganism and the host defense. Polycystic ovary syndrome (PCOS) is a reproductive and metabolic disease associated with increased risk of cardiovascular events. Endocan is a proteoglycan secreted mainly by endothelial cells under the control of inflammatory cytokines. Periodontal diseases, including gingivitis, are common chronic infectious diseases caused by predominantly pathogenic microorganisms that colonize the subgingival area and cause local and systemic elevations of proinflammatory cytokines such as Interleukin-6 (IL-6). Several lines of evidence established the association between periodontal and systemic diseases, including metabolic syndrome, diabetes, and cardiovascular disease. Because of the fact that both periodontal disease and PCOS are associated with systemic inflammation and insulin resistance, these two disorders may be linked through a common pathophysiologic pathway. A number of studies have indicated a possible relationship between PCOS and periodontal inflammation. Despite common risk factors, including oxidative stress, the relationship between chronic periodontitis (CP) and PCOS remains unclear. The aims of the study were to determine serum and saliva Endocan and IL-6 levels and to evaluate the correlation between these two biomarker in women with periodontal disease and PCOS.

Official Title
-----------------
The Levels of Interleukin-6 and Endocan at Individuals With Polycystic Ovary Syndrome and Periodontal Inflammation

Conditions
-----------------
Polycystic Ovary Syndrome, Inflammation Gum, Cytokines

Intervention / Treatment
-----------------
* Diagnostic Test: Collection of Serum and Saliva Samples


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Newly diagnosed PCOS patients Never smokers Had no history of systemic disease BMI<25 kg/m2 Participants had ≥20 teeth present. Exclusion Criteria: Pregnancy Lactation Hemoglobin A1c (HbA1c) ≥ 6.5% 2-h oral glucose tolerance test (OGTT-2h) ≥200 Cushing syndrome, non-classic congenital adrenal hyperplasia, hyperprolactinemia, thyroid dysfunction, and androgen-secreting tumors Using antibiotics and antiinflammatory within the past 6 months Periodontal treatment within the past 6 months

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1<br>PCOS participants with periodontitis | Diagnostic Test: Collection of Serum and Saliva Samples<br>* Whole saliva samples were obtained via expectorating into polypropylene tubes venous blood were obtained from the antecubital vein via the standard venipuncture method.<br>|
| Group 2<br>PCOS participants with periodontally healthy | Diagnostic Test: Collection of Serum and Saliva Samples<br>* Whole saliva samples were obtained via expectorating into polypropylene tubes venous blood were obtained from the antecubital vein via the standard venipuncture method.<br>|
| Group 3<br>systemically healthy participants with periodontitis | Diagnostic Test: Collection of Serum and Saliva Samples<br>* Whole saliva samples were obtained via expectorating into polypropylene tubes venous blood were obtained from the antecubital vein via the standard venipuncture method.<br>|
| Group 4<br>systemically and periodontally healthy participants | Diagnostic Test: Collection of Serum and Saliva Samples<br>* Whole saliva samples were obtained via expectorating into polypropylene tubes venous blood were obtained from the antecubital vein via the standard venipuncture method.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Serum and salivary Endocan levels | Enzyme-Linked Immunosorbent Assay (ELISA) | one year | 
| Serum and salivary interleukin-6 levels | Enzyme-Linked Immunosorbent Assay (ELISA) | one year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical attachment level (CAL) | Periodontal measurement | one year | 
| Probing pocket depth (PD) | Periodontal measurement | one year | 
| Gingival Index | Periodontal measurement | One year |